Company

Abyssinia Biosciences

Biotechnology Research 855 Boylston St 7 employees

Employees: 7
Contacts: 2
Emails: 2

aby-bio.com LinkedIn Crunchbase

Abyssinia Biosciences Overview

Headquarters: 855 Boylston St
Website: aby-bio.com
Industry: Biotechnology Research
Employees: 7
Founded: 2017
Funding: 750.0K
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Immunology CNS Neurodegenerative Disease Alzheimer's Disease Neurodegeneration Biotechnology Dementia Alzheimer's Diagnostics

About Abyssinia Biosciences

On a mission to eradicate neurodegenerative diseases through the precision targeting of toxic misfolded protein aggregates. Our lead candidates ABY-1125 and ABY-1220 are a monoclonal antibodies (mAbs) that selectively bind to the toxic misfolded forms of amyloid-beta. In preclinical studies, ABY-1125 has shown significantly greater selectivity for toxic oligomers in AD brain samples than other amyloid-targeting antibodies therapies currently in clinical development. Moreover, our data confirm that ABY-1125 and ABY-1220 bind to epitopes that are only present in oligomers and that no other mAbs bind to.

Abyssinia Biosciences Contact Details

People in AeroLeads: 3
With contact data: 2
Email contacts: 2; 66.7% coverage

Abyssinia Biosciences Org Chart

Sample employees and titles

Name	Title	Location	Contact
Peter Hoehn	Life Sciences Executive - Commercial	New York, United States	Email
Eric Yuen	Biotechnology and Pharmaceutical	San Mateo, California, United States	Email
Trebor Lawton	Co-founder - Abyssinia Biosciences, Inc.	Exeter, New Hampshire, United States	View